secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2022-12-23T23:59:59+00:00
Accession:  0001193125-22-311788
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium and Metacrine mutually terminate merger; no fee; cash runway extended via Ono partnership
--------------------------------------------------------------------------------

- Merger agreement terminated effective Dec 23, 2022; no termination fee payable.
- CEO cites strategic partnership with Ono Pharmaceutical extending cash runway into 2025.
- Special meeting of stockholders to vote on merger adjourned and now cancelled.
- Equillium focuses on wholly-owned multi-cytokine inhibitors in clinic for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522311788/0001193125-22-311788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312522311788/d396766d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-311788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer